Current progress in dengue vaccines
暂无分享,去创建一个
Robert Anderson | Trai-Ming Yeh | Shuying Wang | Yee‐Shin Lin | Robert Anderson | H-S Liu | Chiou-Feng Lin | T. Yeh | Yee-Shin Lin | Hsiao-Sheng Liu | Chiou-Feng Lin | Yu-Hung Chen | S. Wan | Shu-Wen Wan | Shuying Wang | Yu-Hung Chen
[1] A. Rothman. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms , 2011, Nature Reviews Immunology.
[2] S. Green,et al. Immunopathological mechanisms in dengue and dengue hemorrhagic fever , 2006, Current opinion in infectious diseases.
[3] Saravudh Suvannadabba,et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial , 2012, The Lancet.
[4] A. Barrett,et al. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. , 2007, Vaccine.
[5] A. Rothman,et al. Bystander Target Cell Lysis and Cytokine Production by Dengue Virus-Specific Human CD4+ Cytotoxic T-Lymphocyte Clones , 1999, Journal of Virology.
[6] M. Accavitti-Loper,et al. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. , 2009, Virology.
[7] G. Screaton,et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF , 2010, Proceedings of the National Academy of Sciences.
[8] B. M. Kaufman,et al. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. , 1987, The American journal of tropical medicine and hygiene.
[9] I. Carletti,et al. A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults , 2013, The American journal of tropical medicine and hygiene.
[10] U. Braga-Neto,et al. Alternative Complement Pathway Deregulation Is Correlated with Dengue Severity , 2009, PloS one.
[11] Bjoern Peters,et al. A Protective Role for Dengue Virus-Specific CD8+ T Cells 1 , 2009, The Journal of Immunology.
[12] Yee‐Shin Lin,et al. Deletion of the C-Terminal Region of Dengue Virus Nonstructural Protein 1 (NS1) Abolishes Anti-NS1-Mediated Platelet Dysfunction and Bleeding Tendency1 , 2009, The Journal of Immunology.
[13] J. Sadoff,et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. , 1996, The Journal of infectious diseases.
[14] Yee‐Shin Lin,et al. Factors contributing to the disturbance of coagulation and fibrinolysis in dengue virus infection. , 2013, Journal of the Formosan Medical Association = Taiwan yi zhi.
[15] S. Green,et al. Markers of dengue disease severity. , 2010, Current topics in microbiology and immunology.
[16] D. Sujirarat,et al. The differences of clinical manifestations and laboratory findings in children and adults with dengue virus infection. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[17] P. Mason,et al. Synergistic Interactions between the NS3hel and E Proteins Contribute to the Virulence of Dengue Virus Type 1 , 2012, PLoS neglected tropical diseases.
[18] E. Konishi,et al. Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. , 2002, Vaccine.
[19] Luís Carlos de Souza Ferreira,et al. Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant. , 2012, Vaccine.
[20] A. Falconar,et al. The dengue virus nonstructural-1 protein (NS1) generatesantibodies to common epitopes on human blood clotting,integrin/adhesin proteins and binds to humanendothelial cells: potential implications in haemorrhagic fever pathogenesis , 1997, Archives of Virology.
[21] J. Lang,et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children , 2004, The Pediatric infectious disease journal.
[22] Sophie Yacoub,et al. The pathogenesis of dengue , 2013, Current opinion in infectious diseases.
[23] J. Smit,et al. Role of antibodies in controlling dengue virus infection. , 2009, Immunobiology.
[24] P. Chong,et al. A Novel Single-Dose Dengue Subunit Vaccine Induces Memory Immune Responses , 2011, PloS one.
[25] E. Harris,et al. Recent Advances in Deciphering Viral and Host Determinants of Dengue Virus Replication and Pathogenesis , 2006, Journal of Virology.
[26] S. M. Costa,et al. DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus. , 2006, Vaccine.
[27] J. Schlesinger,et al. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. , 1988, The Journal of general virology.
[28] K. Morita,et al. Dengue and Soluble Mediators of the Innate Immune System , 2011, Tropical medicine and health.
[29] Steven A. Ogata,et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. , 2010, Vaccine.
[30] Yee‐Shin Lin,et al. Generation of IgM anti‐platelet autoantibody in dengue patients , 2001, Journal of medical virology.
[31] D. Clements,et al. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. , 2011, Vaccine.
[32] Alan L Rothman,et al. Dengue: defining protective versus pathologic immunity. , 2004, The Journal of clinical investigation.
[33] S. Inoue,et al. Association of increased platelet‐associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections , 2004, Clinical and experimental immunology.
[34] D. Gubler,et al. Dengue and dengue hemorrhagic fever. , 2014 .
[35] Shuying Wang,et al. Autoimmunity in dengue pathogenesis. , 2013, Journal of the Formosan Medical Association = Taiwan yi zhi.
[36] B. Murphy,et al. A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3′ Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys , 2003, Journal of Virology.
[37] S. M. Costa,et al. DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice. , 2007, Virology.
[38] A. Issekutz,et al. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes , 1997, Journal of virology.
[39] E. Decroly,et al. Structural and functional analysis of methylation and 5'-RNA sequence requirements of short capped RNAs by the methyltransferase domain of dengue virus NS5. , 2007, Journal of molecular biology.
[40] Yee‐Shin Lin,et al. Molecular mimicry between virus and host and its implications for dengue disease pathogenesis , 2011, Experimental biology and medicine.
[41] R. Padmanabhan,et al. Processing and localization of Dengue virus type 2 polyprotein precursor NS3-NS4A-NS4B-NS5 , 1992, Journal of virology.
[42] S. Inoue,et al. Correlation between increased platelet‐associated IgG and thrombocytopenia in secondary dengue virus infections , 2003, Journal of medical virology.
[43] J. Muñoz-Jordán,et al. Inhibition of Alpha/Beta Interferon Signaling by the NS4B Protein of Flaviviruses , 2005, Journal of Virology.
[44] T. Chambers,et al. Neuroblastoma Cell-Adapted Yellow Fever 17D Virus: Characterization of a Viral Variant Associated with Persistent Infection and Decreased Virus Spread , 2002, Journal of Virology.
[45] B. Guy,et al. Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). , 2006, Vaccine.
[46] Angel Balmaseda,et al. Dominant Cross-Reactive B Cell Response during Secondary Acute Dengue Virus Infection in Humans , 2012, PLoS neglected tropical diseases.
[47] O. Horstick,et al. Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries , 2011, BMC infectious diseases.
[48] A. Veerman,et al. Inflammatory Mediators in Dengue Virus Infection in Children: Interleukin-8 and Its Relationship to Neutrophil Degranulation , 2000, Infection and Immunity.
[49] A. Rothman,et al. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. , 2011, The Journal of infectious diseases.
[50] V. Barban,et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. , 2007, Vaccine.
[51] J. Lang,et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. , 2002, The American journal of tropical medicine and hygiene.
[52] Graham S. Ogg,et al. Cellular and Cytokine Correlates of Severe Dengue Infection , 2012, PloS one.
[53] Yee‐Shin Lin,et al. Antibodies from dengue patient sera cross‐react with endothelial cells and induce damage , 2003, Journal of medical virology.
[54] Tao Dong,et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever , 2003, Nature Medicine.
[55] R. Houghten,et al. Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection. , 1991, The Journal of infectious diseases.
[56] J. Schlesinger,et al. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis , 1990, Journal of virology.
[57] Sarah Murrell,et al. Review of dengue virus and the development of a vaccine. , 2011, Biotechnology advances.
[58] R. Rico-Hesse,et al. Report of an NIAID workshop on dengue animal models. , 2010, Vaccine.
[59] R. Rico-Hesse,et al. Dengue Virus Structural Differences That Correlate with Pathogenesis , 1999, Journal of Virology.
[60] Albert D. M. E. Osterhaus,et al. Dengue Virus Pathogenesis: an Integrated View , 2009, Clinical Microbiology Reviews.
[61] E. Harris,et al. Protection from Secondary Dengue Virus Infection in a Mouse Model Reveals the Role of Serotype Cross-Reactive B and T Cells , 2012, The Journal of Immunology.
[62] D. Burke,et al. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. , 1989, The American journal of tropical medicine and hygiene.
[63] R. Warren,et al. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. , 1995, Vaccine.
[64] S. Varga,et al. Protective Heterologous Antiviral Immunity and Enhanced Immunopathogenesis Mediated by Memory T Cell Populations , 1998, The Journal of experimental medicine.
[65] Juan Wang,et al. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: their immunity and protective efficacy in mice. , 2013, Molecular immunology.
[66] J. J. Greene,et al. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. , 2000, Vaccine.
[67] Y. S. Lin,et al. Immunopathogenesis of dengue virus infection. , 2001, Journal of biomedical science.
[68] M. Jacobs,et al. Dengue virus nonstructural protein 1 is expressed in a glycosyl-phosphatidylinositol-linked form that is capable of signal transduction. , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[69] P. Chong,et al. A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. , 2009, Vaccine.
[70] C. Huang,et al. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. , 2012, Vaccine.
[71] J. Lang,et al. Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity , 2011, The Pediatric infectious disease journal.
[72] D. Vaughn,et al. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. , 2003, The American journal of tropical medicine and hygiene.
[73] Shu-Fen Wu,et al. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. , 2003, Vaccine.
[74] R. Chanock,et al. Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys , 1996, Journal of virology.
[75] B. Murphy,et al. Prospects for a dengue virus vaccine , 2007, Nature Reviews Microbiology.
[76] B. Seliger,et al. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. , 1998, Journal of immunology.
[77] A. Nisalak,et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. , 2000, The Journal of infectious diseases.
[78] S. H. Wang,et al. The heterogeneous nuclear ribonucleoprotein K (hnRNP K) interacts with dengue virus core protein. , 2001, DNA and cell biology.
[79] Robert Anderson,et al. Dengue Virus Selectively Induces Human Mast Cell Chemokine Production , 2002, Journal of Virology.
[80] M. Guzmán,et al. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. , 2003, The American journal of tropical medicine and hygiene.
[81] J. Lang,et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. , 2010, The Journal of infectious diseases.
[82] J. Schlesinger,et al. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. , 1987, The Journal of general virology.
[83] P. Yenchitsomanus,et al. Nuclear localization of dengue virus capsid protein is required for DAXX interaction and apoptosis. , 2010, Virus research.
[84] E. Harris,et al. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. , 2012, Virology.
[85] L. Lazo,et al. The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. , 2009, Viral immunology.
[86] L. Sexton. The Treatment of Yellow Fever , 1903, The Indian medical gazette.
[87] T. Yasumoto,et al. Ciguatera fish poisoning on Kakeroma Island, Kagoshima Prefecture, Japan. , 2011 .
[88] Yee‐Shin Lin,et al. Dengue Vaccines: Challenge and Confrontation , 2011 .
[89] P. Niyomrattanakit,et al. Identification of Residues in the Dengue Virus Type 2 NS2B Cofactor That Are Critical for NS3 Protease Activation , 2004, Journal of Virology.
[90] A. Kroeger,et al. Classifying dengue: a review of the difficulties in using the WHO case classification for dengue haemorrhagic fever , 2006, Tropical medicine & international health : TM & IH.
[91] K. Pierce,et al. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. , 2011, Vaccine.
[92] J. Lang,et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. , 2011, Vaccine.
[93] Adolfo García-Sastre,et al. Inhibition of interferon signaling by dengue virus , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[94] A. Nisalak,et al. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. , 1991, The Journal of clinical investigation.
[95] M. Diamond,et al. N-linked glycosylation of dengue virus NS1 protein modulates secretion, cell-surface expression, hexamer stability, and interactions with human complement. , 2011, Virology.
[96] P. Glaziou,et al. Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection. , 1994, The Journal of infectious diseases.
[97] V. Stollar,et al. Newly synthesized dengue-2 virus nonstructural protein NS1 is a soluble protein but becomes partially hydrophobic and membrane-associated after dimerization. , 1989, Virology.
[98] B. Murphy,et al. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. , 2008, The American journal of tropical medicine and hygiene.
[99] R. Padmanabhan,et al. De Novo Synthesis of RNA by the Dengue Virus RNA-dependent RNA Polymerase Exhibits Temperature Dependence at the Initiation but Not Elongation Phase* , 2001, The Journal of Biological Chemistry.
[100] B. Murphy,et al. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Δ30 with those of DEN1 , 2007, Virology Journal.
[101] G. Maga,et al. The RNA helicase, nucleotide 5'-triphosphatase, and RNA 5'-triphosphatase activities of Dengue virus protein NS3 are Mg2+-dependent and require a functional Walker B motif in the helicase catalytic core. , 2004, Virology.
[102] R. Chanock,et al. Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a , 1989, Journal of virology.
[103] Suresh Mahalingam,et al. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes , 2010, The Lancet Infectious Diseases.
[104] A. Sampath,et al. Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA. , 2006, The Journal of general virology.
[105] A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates , 2013, Archives of Virology.
[106] M. Guzmán,et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. , 2006, Vaccine.
[107] R. Edelman,et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. , 2003, The American journal of tropical medicine and hygiene.
[108] S. Swaminathan,et al. Replication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Dengue Virus Type 2 , 2003, Journal of Virology.
[109] D. Vaughn,et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. , 2005, Vaccine.
[110] M. Guzmán,et al. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. , 2009, International immunology.
[111] F. Guirakhoo,et al. Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates , 2004, Journal of Virology.
[112] Rosanna W. Peeling,et al. Dengue: a continuing global threat , 2010, Nature Reviews Microbiology.
[113] J. An,et al. Dengue-specific CD8+ T cells have both protective and pathogenic roles in dengue virus infection. , 2004, Immunology letters.
[114] R. Schlesinger,et al. Dengue Viruses , 1977, Virology Monographs Die Virusforschung in Einzeldarstellungen.
[115] J. Lepault,et al. Dengue Virus Type 1 Nonstructural Glycoprotein NS1 Is Secreted from Mammalian Cells as a Soluble Hexamer in a Glycosylation-Dependent Fashion , 1999, Journal of Virology.
[116] Cameron P Simmons,et al. The pathogenesis of dengue. , 2011, Vaccine.
[117] K. Morita,et al. Molecular evolution, distribution and genetic relationship among the dengue 2 viruses isolated from different clinical severity. , 2000, The Southeast Asian journal of tropical medicine and public health.
[118] Yee‐Shin Lin,et al. The Dual-Specific Binding of Dengue Virus and Target Cells for the Antibody-Dependent Enhancement of Dengue Virus Infection1 , 2006, The Journal of Immunology.
[119] B. Murphy,et al. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2 , 2004, BMC infectious diseases.
[120] Yee‐Shin Lin,et al. Autoimmune pathogenesis in dengue virus infection. , 2006, Viral immunology.
[121] Lauren E. Yauch,et al. Mouse models of dengue virus infection and disease. , 2008, Antiviral research.
[122] S. Halstead,et al. How Innate Immune Mechanisms Contribute to Antibody-Enhanced Viral Infections , 2010, Clinical and Vaccine Immunology.
[123] Cameron P. Simmons,et al. Current concepts: Dengue , 2012 .
[124] M. Rossmann,et al. Molecular mechanisms involved in the early steps of flavivirus cell entry. , 2011, Microbes and infection.
[125] S. Kalayanarooj,et al. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. , 2010, The Journal of infectious diseases.
[126] R. Rico-Hesse,et al. American Genotype Structures Decrease Dengue Virus Output from Human Monocytes and Dendritic Cells , 2003, Journal of Virology.
[127] A. Davidson,et al. Mutagenesis of the Dengue Virus Type 2 NS3 Protein within and outside Helicase Motifs: Effects on Enzyme Activity and Virus Replication , 2001, Journal of Virology.
[128] A. Rothman,et al. Altered Cytokine Responses of Dengue-Specific CD4+ T Cells to Heterologous Serotypes 1 , 2005, The Journal of Immunology.
[129] Alfonso Gúzman,et al. Update on the global spread of dengue. , 2010, International journal of antimicrobial agents.
[130] B. Murphy,et al. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. , 2004, The American journal of tropical medicine and hygiene.
[131] Stephen J. Thomas,et al. Critical issues in dengue vaccine development , 2011, Current opinion in infectious diseases.
[132] A. D. de Silva,et al. The Human Antibody Response to Dengue Virus Infection , 2011, Viruses.
[133] M. Blettner,et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. , 2006, The Journal of infectious diseases.
[134] Cameron P. Simmons,et al. An In-Depth Analysis of Original Antigenic Sin in Dengue Virus Infection , 2010, Journal of Virology.
[135] A. Yueh,et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. , 2009, Microbes and infection.
[136] Ralf Bartenschlager,et al. Composition and Three-Dimensional Architecture of the Dengue Virus Replication and Assembly Sites , 2009, Cell Host & Microbe.
[137] S. Halstead,et al. Dengue vaccine development: a 75% solution? , 2012, The Lancet.
[138] J. Chin,et al. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. , 2007, Microbes and infection.
[139] T. Kinoshita,et al. Association of dengue virus NS1 protein with lipid rafts. , 2008, The Journal of general virology.
[140] B. Moss,et al. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. , 2000, Vaccine.
[141] T. Peng,et al. The Animal Models for Dengue Virus Infection , 2004 .
[142] B. Murphy,et al. Immune response to dengue virus and prospects for a vaccine. , 2011, Annual review of immunology.
[143] A. Falconar. Antibody Responses Are Generated to Immunodominant ELK/KLE-Type Motifs on the Nonstructural-1 Glycoprotein during Live Dengue Virus Infections in Mice and Humans: Implications for Diagnosis, Pathogenesis, and Vaccine Design , 2007, Clinical and Vaccine Immunology.
[144] S. Halstead,et al. Neutralization and antibody-dependent enhancement of dengue viruses. , 2003, Advances in virus research.
[145] N. Bhamarapravati,et al. Live attenuated tetravalent dengue vaccine. , 2000, Vaccine.